261 related articles for article (PubMed ID: 9474130)
1. En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes.
Nash PA; Leibovitch I; Foster RS; Bihrle R; Rowland RG; Donohue JP
J Urol; 1998 Mar; 159(3):707-10. PubMed ID: 9474130
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer.
Stephenson AJ; Tal R; Sheinfeld J
J Urol; 2006 Nov; 176(5):1996-9; discussion 1999. PubMed ID: 17070234
[TBL] [Abstract][Full Text] [Related]
3. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.
Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz BJ; Figlin RA; Belldegrun AS
J Urol; 2003 Jun; 169(6):2076-83. PubMed ID: 12771723
[TBL] [Abstract][Full Text] [Related]
4. Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection.
Beck SD; Foster RS; Bihrle R; Koch MO; Wahle GR; Donohue JP
J Urol; 2001 May; 165(5):1517-20. PubMed ID: 11342909
[TBL] [Abstract][Full Text] [Related]
5. Retroperitoneal lymph node dissection in patients with high risk testicular cancer.
Williams SB; McDermott DW; Dock W; Bahnson E; Berry AM; Steele GS; Richie JP
J Urol; 2009 May; 181(5):2097-101; discussion 2101-2. PubMed ID: 19286227
[TBL] [Abstract][Full Text] [Related]
6. Incidence, histology and management of intraluminal thrombus at post-chemotherapy retroperitoneal lymph node dissection.
Johnston P; Beck SD; Cheng L; Masterson TA; Bihrle R; Kesler K; Foster RS
J Urol; 2013 Sep; 190(3):874-7. PubMed ID: 23517745
[TBL] [Abstract][Full Text] [Related]
7. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
Carver BS; Bianco FJ; Shayegan B; Vickers A; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2006 Jul; 176(1):100-3; discussion 103-4. PubMed ID: 16753380
[TBL] [Abstract][Full Text] [Related]
8. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer.
Coogan CL; Hejase MJ; Wahle GR; Foster RS; Rowland RG; Bihrle R; Donohue JP
J Urol; 1996 Nov; 156(5):1656-8. PubMed ID: 8863564
[TBL] [Abstract][Full Text] [Related]
9. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
10. Repeat retroperitoneal lymph node dissection for metastatic testis cancer.
Sexton WJ; Wood CG; Kim R; Pisters LL
J Urol; 2003 Apr; 169(4):1353-6. PubMed ID: 12629359
[TBL] [Abstract][Full Text] [Related]
11. Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer.
Steiner H; Zangerl F; Stöhr B; Granig T; Ho H; Bartsch G; Peschel R
J Urol; 2008 Oct; 180(4):1348-52; discussion 1352-3. PubMed ID: 18707723
[TBL] [Abstract][Full Text] [Related]
12. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?
Mosharafa AA; Foster RS; Leibovich BC; Bihrle R; Johnson C; Donohue JP
J Urol; 2003 Jun; 169(6):2126-8. PubMed ID: 12771733
[TBL] [Abstract][Full Text] [Related]
13. Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer.
Williams SB; Steele GS; Richie JP
J Urol; 2009 Dec; 182(6):2716-20. PubMed ID: 19836777
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathological features predictive of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection.
Cary KC; Beck SD; Bihrle R; Foster RS
J Urol; 2013 Mar; 189(3):812-7. PubMed ID: 23017517
[TBL] [Abstract][Full Text] [Related]
15. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection.
Spiess PE; Brown GA; Liu P; Tu SM; Tannir NM; Evans JG; Kamat AM; Kassouf W; Pisters LL
J Urol; 2007 Jan; 177(1):131-8. PubMed ID: 17162023
[TBL] [Abstract][Full Text] [Related]
16. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone.
Coogan CL; Foster RS; Rowland RG; Bihrle R; Smith ER; Einhorn LH; Roth BJ; Donohue JP
Urology; 1997 Dec; 50(6):957-62. PubMed ID: 9426730
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
18. Does the presence of extranodal extension in pathological stage B1 nonseminomatous germ cell tumor necessitate adjuvant chemotherapy?
Beck SD; Cheng L; Bihrle R; Donohue JP; Foster RS
J Urol; 2007 Mar; 177(3):944-6. PubMed ID: 17296383
[TBL] [Abstract][Full Text] [Related]
19. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group.
Heidenreich A; Albers P; Hartmann M; Kliesch S; Kohrmann KU; Krege S; Lossin P; Weissbach L;
J Urol; 2003 May; 169(5):1710-4. PubMed ID: 12686815
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
